keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer her2+ recurrence

keyword
https://www.readbyqxmd.com/read/27904700/detection-of-gene-copy-number-alterations-in-dcis-and-invasive-breast-cancer-by-qm-fish
#1
Aifeng Pan, Yawei Zhou, Kun Mu, Yansong Liu, Feifei Sun, Peng Li, Li Li
The exact roles of copy number alteration (CNA) in initiation, progression and immunotherapy of breast cancer and the genomic alterations behind progression from ductal carcinoma in situ (DCIS) to invasive carcinoma remain unknown. Quantitative multi-gene fluorescence in situ hybridization (QM-FISH) opens a possibility of large scale genomic analysis of specific deletions and amplifications with high-resolution at one cell level. We detected CNAs of 30 genes using QM-FISH and analyzed their association with clinicopathological parameters and patients' outcomes in 66 breast cancers with synchronous invasive carcinoma and DCIS...
2016: American Journal of Translational Research
https://www.readbyqxmd.com/read/27900589/intrinsic-her2-v777l-mutation-mediates-resistance-to-trastuzumab-in-a-breast-cancer-patient
#2
Yosuke Hirotsu, Hiroshi Nakagomi, Kenji Amemiya, Toshio Oyama, Masayuki Inoue, Hitoshi Mochizuki, Masao Omata
HER2 (ERBB2) is an oncogene and 20% of breast cancers display HER2 amplification. The HER2 monoclonal antibody, trastuzumab, is used to treat breast cancers that display HER2 amplification, with good responses in 80-90% of cases; however, 10% of tumours develop resistance to trastuzumab. In this study, we collected data of primary breast cancer patients who treated at hospital during 2004-2014. In our cohort, 205 of 1497 primary breast cancer patients showed HER2-amplification, and 20 experienced recurrence after trastuzumab therapy...
January 2017: Medical Oncology
https://www.readbyqxmd.com/read/27899774/-a-review-multigene-assays-for-clinical-utility-in-breast-cancer
#3
Kazuhiro Araki, Yoshinori Ito
Multigene assays that simultaneously measure the expression of various breast cancer genes have been developed to guide the use of adjuvant chemotherapy in early breast cancer. The efficacy of adjuvant therapies depends on the recurrence risk for an individual patient. As a result, accurate prediction of the recurrence risk is vital for precise adjuvant chemotherapy in individual breast cancer patients. The recurrence risk as typically assessed by conventional examination of histological data of immuno-histological biomarkers(ER, PR, HER2, and Ki-67)is not sufficient to select subsets of patients...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27894048/real-world-patterns-of-care-in-her2-overexpressing-breast-cancer-results-of-a-survey-of-teach-clinical-trial-investigators-in-2011
#4
Y Chavarri-Guerra, J St Louis, A Bukowski, E Soto-Perez-de-Celis, P E R Liedke, H Symecko, B Moy, M Higgins, D M Finkelstein, P E Goss
BACKGROUND: HER2-overexpressing breast cancer (BC) is common among young patients and poses a public health burden. Adjuvant anti-HER2/neu therapy with trastuzumab reduces the risk of recurrence and improves survival. METHODS: A web-based survey was sent to 386 physicians of the "TEACH" trial in 2011 to determine access to HER2/neu testing and treatment patterns for HER2-overexpressing BC. RESULTS: There were 151 responders (39%) from 28 countries...
November 25, 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27893626/molecular-profiling-using-breast-cancer-subtype-to-plan-for-breast-reconstruction
#5
Lars Johan Sandberg, Mark W Clemens, W F Symmans, Vicente Valero, Abigail S Caudle, Benjamin Smith, Henry M Kuerer, Limin Hsu, Steven J Kronowitz
BACKGROUND: Molecular profiling using breast cancer subtype has an increasing role in the multidisciplinary care of the breast cancer patient. We sought to determine the role of breast cancer subtyping in breast reconstruction and specifically if breast cancer subtyping can determine the need for postmastectomy radiation therapy (PMRT) and predict recurrence-free survival (RFS) to plan for the timing and technique of breast reconstruction. METHODS: We reviewed prospectively collected data from 1931 reconstructed breasts in breast cancer patients who underwent mastectomy between November 1999 and December 2012...
November 21, 2016: Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/27885422/cd44-induces-foxp3-expression-and-is-related-with-favorable-outcome-in-breast-carcinoma
#6
Elena Sanmartín, Fernando Ortiz-Martínez, Eloy Pomares-Navarro, Araceli García-Martínez, Montserrat Rodrigo-Baños, Marta García-Escolano, Leire Andrés, Enrique Lerma, Francisco I Aranda, Pascual Martínez-Peinado, José M Sempere-Ortells, Gloria Peiró
We studied the relationship between CD44 and Forkhead box P3 (FOXP3) gene expression in cell lines and breast carcinomas and their association with clinicopathological variables and patient outcome. We assessed messenger RNA (mRNA) expression of CD44 and FOXP3 by quantitative real-time PCR and determined the number of FOXP3+ Tregs by immunohistochemistry in 264 breast cancer specimens. CD44 was stimulated with hyaluronan treatment, and the accompanying changes in FOXP3 mRNA expression in breast cancer cell lines representing breast cancer subtype were assessed...
November 24, 2016: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/27881013/feat-expression-correlates-with-tumor-size-pr-status-her2-expression-ki67-index-and-molecular-subtype-and-predicts-recurrence-in-breast-cancer
#7
S M Wang, M Ye, J Zhou, S M Ni, Q C Wei
FEAT protein is uniformly overexpressed in a variety of human cancers but weakly expressed in normal tissue. FEAT has antiapoptotic activity and plays a role in carcinogenesis; however, the correlation between FEAT and clinicopathologic characteristics in cancer has not been reported. Our study explores the expression of FEAT protein and its clinicopathologic significance in breast cancer. We examined the expression of FEAT in tissues from 131 cases of breast cancer by immunohistochemistry and analyzed the correlation between FEAT expression and clinicopathologic parameters...
November 24, 2016: Neoplasma
https://www.readbyqxmd.com/read/27872526/progesterone-receptors-pathological-complete-response-and-early-outcome-for-locally-advanced-breast-cancer-a-single-centre-study-pplb-01
#8
Sanjit Agrawal, Lalit Banswal, Animesh Saha, Indu Arun, Soumitra Shankar Datta, Sanjoy Chatterjee, Rosina Ahmed
Neoadjuvant chemotherapy (NACT) for locally advanced breast cancer (LABC), apart from increasing breast conservation rates, also provides an opportunity to assess tumour response to chemotherapy, with Pathological Complete Response (pCR) described as an independent prognostic factor and a surrogate marker for better outcome and survival. Our primary aim was to identify clinical and pathological factors associated with pCR following NACT in patients with LABC treated at our institution. Our secondary aim was to analyze the impact of pCR and associated factors on disease free survival (DFS) and overall survival (OS)...
December 2016: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27856201/daily-practice-management-of-pt1a-b-pn0-breast-carcinoma-a-prospective-french-odissee-cohort-study
#9
Florence Dalenc, Frédérique Penault-Llorca, Monique Cohen, Gilles Houvenaeghel, Jean-Marc Piat, Philippe Liegeois, Laurent Puyuelo, Jean-Philippe Suchaud, Mohammed Zouai, Magali Lacroix-Triki, Nina Radosevic-Robin, Chahinez Benkanoun, Hanane Attar-Rabia, Marie-Pierre Chauvet, Joseph Gligorov, Yazid Belkacemi
BACKGROUND: Most breast cancer (BC) tumors ≤10 mm have an excellent prognosis. The subgroups with a higher risk for distant recurrence requiring adjuvant systemic therapy are not precisely defined in current international guidelines. PATIENTS AND METHODS: The OBSERVATOIRE DES PETITS CANCERS DU SEIN HER2 +/- (ODISSEE) study was a prospective, multicenter, cohort study that aimed to describe the daily adjuvant management and outcome of 616 patients with unifocal, invasive pT1a-b pN0 nonmetastatic BC who underwent surgery...
August 31, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27853985/a-definition-for-aggressive-disease-in-patients-with-her-2-negative-metastatic-breast-cancer-an-expert-consensus-of-the-spanish-society-of-medical-oncology-seom
#10
REVIEW
A González, A Lluch, E Aba, J Albanell, A Antón, I Álvarez, F Ayala, A Barnadas, L Calvo, E Ciruelos, J Cortés, J de la Haba, J M López-Vega, E Martínez, M Muñoz, I Peláez, A Redondo, Á Rodríguez, C A Rodríguez, A Ruíz, A Llombart
PURPOSE: To converge on an expert opinion to define aggressive disease in patients with HER2-negative mBC using a modified Delphi methodology. METHODS: A panel of 21 breast cancer experts from the Spanish Society of Medical Oncology agreed upon a survey which comprised 47 questions that were grouped into three sections: relevance for defining aggressive disease, aggressive disease criteria and therapeutic goals. Answers were rated using a 9-point Likert scale of relevance or agreement...
November 16, 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27851873/mri-surveillance-of-cancer-cell-fate-in-a-brain-metastasis-model-after-early-radiotherapy
#11
Donna H Murrell, Niloufar Zarghami, Michael D Jensen, Fiona Dickson, Ann F Chambers, Eugene Wong, Paula J Foster
PURPOSE: Incidence of brain metastasis attributed to breast cancer is increasing and prognosis is poor. It is thought that disseminated dormant cancer cells persist in metastatic organs and may evade treatments, thereby facilitating a mechanism for recurrence. Radiotherapy is used to treat brain metastases clinically, but assessment has been limited to macroscopic tumor volumes detectable by clinical imaging. Here, we use cellular MRI to understand the concurrent responses of metastases and nonproliferative or slowly cycling cancer cells to radiotherapy...
November 14, 2016: Magnetic Resonance in Medicine: Official Journal of the Society of Magnetic Resonance in Medicine
https://www.readbyqxmd.com/read/27846764/impact-of-age-intrinsic-subtype-and-local-treatment-on-long-term-local-regional-recurrence-and-breast-cancer-mortality-among-low-risk-breast-cancer-patients
#12
Tinne Laurberg, Jan Alsner, Trine Tramm, Vibeke Jensen, Christina D Lyngholm, Peer M Christiansen, Jens Overgaard
AIM: To evaluate the long-term prognostic impact of age, local treatment and intrinsic subtypes on the risk of local-regional recurrence (LRR) and breast cancer mortality among low-risk patients. MATERIAL AND METHODS: Cohort study with prospectively collected data, balanced five-year age groups, including 514 Danish lymph node negative breast cancer patients diagnosed between 1989 and 1998, treated with mastectomy (N = 320) or breast-conserving therapy (BCT) (N = 194) and without systemic treatment...
November 16, 2016: Acta Oncologica
https://www.readbyqxmd.com/read/27835789/a-comparative-performance-analysis-of-multispectral-and-rgb-imaging-on-her2-status-evaluation-for-the-prediction-of-breast-cancer-prognosis
#13
Wenlou Liu, Linwei Wang, Jiuyang Liu, Jingping Yuan, Jiamei Chen, Han Wu, Qingming Xiang, Guifang Yang, Yan Li
Despite the extensive application of multispectral imaging (MSI) in biomedical multidisciplinary researches, there is a paucity of data available regarding the implication of MSI in tumor prognosis prediction. We compared the behaviors of multispectral (MS) and conventional red-green-blue (RGB) images on assessment of human epidermal growth factor receptor 2 (HER2) immunohistochemistry to explore their impact on outcome in patients with invasive breast cancer (BC). Tissue microarrays containing 240 BC patients were introduced to compare the performance of MS and RGB imaging methods on the quantitative assessment of HER2 status and the prognostic value of 5-year disease-free survival (5-DFS)...
November 8, 2016: Translational Oncology
https://www.readbyqxmd.com/read/27822058/double-edged-role-of-g-protein-coupled-estrogen-receptor-1-in-breast-cancer-prognosis-an-analysis-of-167-breast-cancer-samples-and-online-data-sets
#14
Fan Yang, Zhi-Min Shao
G protein-coupled estrogen receptor 1 (GPER1) is widely expressed in breast cancer; however, its prognostic significance in breast cancer patients remains controversial. In this study, expression levels of GPER1 were analyzed by using real-time polymerase chain reaction in 167 primary breast cancer samples, and overall survival (OS), recurrence-free survival (RFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS) were analyzed by using Kaplan-Meier curves and multivariable Cox regression...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27815936/microrna-124-enhances-response-to-radiotherapy-in-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-cells-by-targeting-signal-transducer-and-activator-of-transcription-3
#15
Ying Fu, Jianping Xiong
AIM: To determine whether microRNA (miR)-124 enhances the response to radiotherapy in human epidermal growth factor receptor 2 (HER2)-positive breast cancer cells by targeting signal transducer and activator of transcription 3 (Stat3). METHODS: miR-29b expression was measured in 80 pairs of breast tumor samples and adjacent normal tissues collected between January 2013 and July 2014. Activity changes of 50 canonical signaling pathways upon miR-124 overexpression were determined using Cignal Signal Transduction Reporter Array...
October 31, 2016: Croatian Medical Journal
https://www.readbyqxmd.com/read/27811364/erbb2-mutation-is-associated-with-a-worse-prognosis-in-patients-with-cdh1-altered-invasive-lobular-cancer-of-the-breast
#16
Zheng Ping, Gene P Siegal, Shuko Harada, Isam-Eldin Eltoum, Mariam Youssef, Tiansheng Shen, Jianbo He, Yingjie Huang, Dongquan Chen, Yiping Li, Kirby I Bland, Helena R Chang, Dejun Shen
E-cadherin (CDH1) is a glycoprotein that mediates adhesion between epithelial cells and also suppresses cancer invasion. Mutation or deletion of the CDH1 gene has been reported in 30-60% cases of invasive lobular carcinoma (ILC). However, little is known about genomic differences between ILC with and without a CDH1 alteration. Therefore, we analyzed whole genome sequencing data of 169 ILC cases from The Cancer Genome Atlas (TCGA) to address this deficiency. Our study shows that CDH1 gene was altered in 59.2% (100/169) of ILC...
November 2, 2016: Oncotarget
https://www.readbyqxmd.com/read/27810699/improved-survival-in-metastatic-breast-cancer-1985-2016
#17
Marie Sundquist, Lars Brudin, Göran Tejler
PURPOSE: In the last 25 years new treatment options in breast cancer have evolved. We wanted to determine whether the survival of; patients with metastatic breast cancer have improved during this period. METHODS: Patients consecutively diagnosed with disseminated breast cancer 1985-2014 in the County of Kalmar, Sweden, were identified and followed to 2016. Survival was calculated for each successive 5 year interval. Separate analyses were performed for pts with ER and/or PR and HER2 positive tumours resp...
October 28, 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27807809/breast-cancer-subtype-age-and-lymph-node-status-as-predictors-of-local-recurrence-following-breast-conserving-therapy
#18
Lior Z Braunstein, Alphonse G Taghian, Andrzej Niemierko, Laura Salama, Alexander Capuco, Jennifer R Bellon, Julia S Wong, Rinaa S Punglia, Shannon M MacDonald, Jay R Harris
PURPOSE/OBJECTIVES: Advances in breast-conserving therapy (BCT) have yielded local control rates comparable or superior to those of mastectomy. In this study, we sought to identify contemporary risk factors associated with local recurrence (LR) following BCT. METHODS: We analyzed a multi-institutional cohort of 2233 consecutive breast-cancer patients who underwent BCT between 1998 and 2007. Patients were stratified by age, biologic subtype (as approximated by receptor status and tumor grade), and nodal status...
November 3, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27806348/clinical-outcomes-based-on-multigene-profiling-in-metastatic-breast-cancer-patients
#19
Reva K Basho, Debora de Melo Gagliato, Naoto T Ueno, Chetna Wathoo, Huiqin Chen, Maryam Shariati, Caimiao Wei, Ricardo H Alvarez, Stacy L Moulder, Aysegul A Sahin, Sinchita Roy-Chowdhuri, Mariana Chavez-MacGregor, Jennifer K Litton, Vincent Valero, Raja Luthra, Jia Zeng, Kenna R Shaw, John Mendelsohn, Gordon B Mills, Debu Tripathy, Funda Meric-Bernstam
BACKGROUND: Identifying the clinical impact of recurrent mutations can help define their role in cancer. Here, we identify frequent hotspot mutations in metastatic breast cancer (MBC) patients and associate them with clinical outcomes. PATIENTS AND METHODS: Hotspot mutation testing was conducted in 500 MBC patients using an 11 gene (N = 126) and/or 46 or 50 gene (N = 391) panel. Patients were stratified by hormone receptor (HR) and human epidermal growth factor 2 (HER2) status...
October 28, 2016: Oncotarget
https://www.readbyqxmd.com/read/27787892/associations-between-use-of-the-21-gene-recurrence-score-assay-and-chemotherapy-regimen-selection-in-a-statewide-registry
#20
N Lynn Henry, Thomas M Braun, Haythem Y Ali, Khan Munir, Samuel M Silver, David H Gorski, Tara M Breslin, Jennifer J Griggs
BACKGROUND: The 21-gene recurrence score (RS) assay predicts response to adjuvant chemotherapy in patients with early-stage, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancer, but to the authors' knowledge, the role of the assay in guiding the selection of chemotherapy regimen has not been established. The current study was conducted to examine patterns of use of the RS assay for selecting chemotherapy regimens across a statewide registry from 2006 through 2013...
October 27, 2016: Cancer
keyword
keyword
115348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"